62 related articles for article (PubMed ID: 29047029)
1. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
Kato S; Jardim DL; Johnson FM; Subbiah V; Piha-Paul S; Tsimberidou AM; Falchook GS; Karp D; Zinner R; Wheler J; Janku F; Fu S; Lim J; Bean S; Nguyen L; Urban S; Browne E; Meric-Bernstam F; Hong DS
Invest New Drugs; 2018 Jun; 36(3):416-423. PubMed ID: 29047029
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD; Kollmannsberger CK; Sukhai MA; Takebe N; Kamel-Reid S; Siu LL; Hotte SJ
Invest New Drugs; 2014 Oct; 32(5):1005-16. PubMed ID: 24788563
[TBL] [Abstract][Full Text] [Related]
3. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.
D'Angelo SP; Shoushtari AN; Keohan ML; Dickson MA; Gounder MM; Chi P; Loo JK; Gaffney L; Schneider L; Patel Z; Erinjeri JP; Bluth MJ; Sjoberg A; Streicher H; Takebe N; Qin LX; Antonescu C; DeMatteo RP; Carvajal RD; Tap WD
Clin Cancer Res; 2017 Jun; 23(12):2972-2980. PubMed ID: 28007774
[No Abstract] [Full Text] [Related]
4. Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.
Piscitani L; Sirolli V; Di Liberato L; Morroni M; Bonomini M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664269
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.
Scott AJ; Song EK; Bagby S; Purkey A; McCarter M; Gajdos C; Quackenbush KS; Cross B; Pitts TM; Tan AC; Eckhardt SG; Fenton H; Arcaroli J; Messersmith WA
PLoS One; 2017; 12(11):e0187173. PubMed ID: 29091939
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.
Leighl NB; Tsao MS; Liu G; Tu D; Ho C; Shepherd FA; Murray N; Goffin JR; Nicholas G; Sakashita S; Chen Z; Kim L; Powers J; Seymour L; Goss G; Bradbury PA
Oncotarget; 2017 Sep; 8(41):69651-69662. PubMed ID: 29050231
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V; Groisberg R; Hess K; Fu S; Wheler J; Hong DS; Janku F; Zinner R; Piha-Paul SA; Ravi V; Benjamin RS; Patel S; Somaiah N; Herzog CE; Karp DD; Roszik J; Meric-Bernstam F; Subbiah V
Sci Rep; 2017 Nov; 7(1):15963. PubMed ID: 29162825
[TBL] [Abstract][Full Text] [Related]
8. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.
Ocana A; Gil-Martin M; Martín M; Rojo F; Antolín S; Guerrero Á; Trigo JM; Muñoz M; Pandiella A; Diego NG; Bezares S; Caballero R; Carrasco E; Urruticoechea A
Oncotarget; 2017 Sep; 8(42):73144-73153. PubMed ID: 29069857
[TBL] [Abstract][Full Text] [Related]
10. A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.
Yam C; Xu X; Davies MA; Gimotty PA; Morrissette JJD; Tetzlaff MT; Wani KM; Liu S; Deng W; Buckley M; Zhao J; Amaravadi RK; Haas NB; Kudchadkar RR; Pavlick AC; Sosman JA; Tawbi H; Walker L; Schuchter LM; Karakousis GC; Gangadhar TC
Clin Cancer Res; 2018 Jan; 24(1):22-32. PubMed ID: 29051322
[No Abstract] [Full Text] [Related]
11. The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated
Murakami Y; Sonoda K; Abe H; Watari K; Kusakabe D; Azuma K; Kawahara A; Akiba J; Oneyama C; Pachter JA; Sakai K; Nishio K; Kuwano M; Ono M
Oncotarget; 2017 Sep; 8(41):70736-70751. PubMed ID: 29050315
[TBL] [Abstract][Full Text] [Related]
12. Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines.
Zhao WH; Huang BT; Zhang JY; Zeng QC
Leuk Res; 2017 Dec; 63():28-33. PubMed ID: 29096333
[TBL] [Abstract][Full Text] [Related]
13. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.
Dzimitrowicz H; Mougalian S; Storms S; Hurd S; Chagpar AB; Killelea BK; Horowitz NR; Lannin DR; Harigopal M; Hofstatter E; DiGiovanna MP; Adelson KB; Silber A; Abu-Khalaf M; Chung G; Zaheer W; Abdelghany O; Hatzis C; Pusztai L; Sanft TB
J Oncol Pract; 2017 Dec; 13(12):e1012-e1020. PubMed ID: 29048991
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
15. Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
Wu YL; Lu S; Lu Y; Zhou J; Shi YK; Sriuranpong V; Ho JCM; Ong CK; Tsai CM; Chung CH; Wilner KD; Tang Y; Masters ET; Selaru P; Mok TS
J Thorac Oncol; 2018 Oct; 13(10):1539-1548. PubMed ID: 29966800
[TBL] [Abstract][Full Text] [Related]
16. Evidence-Based Recommendations for Education Provided to Patients and Families Regarding the Adverse Events of ALK and MEK Inhibitors: A Systematic Review From the Children's Oncology Group.
Fisher B; Meyer A; Brown A; Conway Keller M; McKeown T; Tiller J; Saylor KM; Duffy EA
J Pediatr Hematol Oncol Nurs; 2024; 41(2):114-128. PubMed ID: 38549368
[No Abstract] [Full Text] [Related]
17. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment.
Frumento D; Grossi G; Falesiedi M; Musumeci F; Carbone A; Schenone S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338677
[TBL] [Abstract][Full Text] [Related]
18. Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma.
Salguero-Aranda C; Olmedo-Pelayo J; de Álava E; Amaral AT; Díaz-Martín J
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551696
[TBL] [Abstract][Full Text] [Related]
19. The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents.
Grundy M; Narendran A
Front Pediatr; 2022; 10():910268. PubMed ID: 36034555
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Cabozantinib in Patients With Bone Metastasis.
Choy E; Cote GM; Michaelson MD; Wirth L; Gainor JF; Muzikansky A; Sequist LV; Sullivan RJ; Fidias PM; Shaw A; Heist RS
Oncologist; 2022 Jul; 27(7):600-606. PubMed ID: 35524758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
